1. Nausea and vomiting in pregnancy (NVP) as an evolutionary adaptation to prevent fetal exposure to neurotoxins. (Dr. Adam Kirton)
Models of evolutionary medicine and preliminary evidence support the role of NVP as an evolutionary adaptation to prevent fetal toxin exposure. We hypothesize that NVP is inversely correlated with the risk of neurodevelopmental disorders in children. Confirmation and analysis of this model could identify preventative measures.
2. Materno-Fetal Outcomes in Inflammatory Bowel Disease (IBD) Patients Exposed to Biologic Therapy. (Dr. Cynthia Seow)
The aim of this proposed study is to determine if the rate of adverse outcomes is higher among women with IBD and individuals born to mothers with IBD (stratified by therapeutic agents with particular interest in the biologic agents) compared to those without IBD by establishing a prospective Canada wide registry of pregnant and lactating women with IBD. Individuals born to mothers with IBD will be followed from birth to 3 years of age. Prospective determination of the safety of therapeutic agents in the mother with IBD, the developing fetus, and the child will be studied using a combination of clinical, serologic, pharmacokinetic and genetic data.
3. Serum Vitamin D levels in pregnant women and their newborns in two hospital centers in Calgary (Dr. Fariba Aghajafari, Dr. Maeve O’Beirne, Dr. Sue Ross)
The aim of the pilot project is to determine the level of 25(OH) D (the best indicator of overall Vitamin D status is serum) in pregnant mothers (at the time of delivery) and their newborn infants (cord blood), and its association with pregnancy complications and birth outcomes.
4. Does exposure to high levels of outdoor pollutants result in poor neonatal or neurodevelopmental outcomes? (Dr. Gil Kaplan)
The purpose of this project is to assess if exposure to high levels of residential outdoor air pollutants (nitrogen dioxide, sulfur dioxide, carbon monoxide, ozone, and particulate matter) throughout pregnancy will result in poor neonatal outcomes (i.e. prematurity, intrauterine growth restriction, and congenital abnormalities) and childhood neurodevelopmental disorders.